News for Lantern Pharma Inc Registered Shs

Market Watch 7d

: Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week

MarketWatch 7d

: Lantern Pharma had no exposure to Silicon Valley Bank

Seeking Alpha 14d

Lantern forms unit Starlight focused on CNS disorders, brain cancers

InvestorPlace 26d

7 AI Penny Stocks That Could Skyrocket in 2023

TipRanks 32d

EF Hutton Sticks to Their Buy Rating for Lantern Pharma (LTRN)

Seeking Alpha 74d

FDA grants orphan drug designation to Lantern Pharma's lymphoma treatment candidate

Seeking Alpha 132d

Lantern Pharma GAAP EPS of -$0.21 beats by $0.27

Benzinga 138d

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Seeking Alpha 223d

Lantern Pharma GAAP EPS of -$0.41 beats by $0.11

Seeking Alpha 248d

Sunrun, 10x Genomics, Innovative Industrial Properties among premarket losers' pack

Benzinga 249d

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures

Seeking Alpha 249d

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Seeking Alpha 320d

Lantern Pharma GAAP EPS of -$0.38

Benzinga 321d

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs

Seeking Alpha 363d

Lantern Pharma board extends existing share repurchase program

Seeking Alpha 374d

Lantern Pharma GAAP EPS of -$1.13 misses by $0.74

Benzinga 378d

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg

Benzinga 416d

Benzinga Announces This Week's All Access Guests

Seeking Alpha 420d

Lantern Pharma up 11% on Rare Pediatric Disease and Orphan Drug tag for LP-184 for ATRT

Seeking Alpha 431d

Lantern Pharma rises 9% on team up with National Cancer Institute for drug candidates

Seeking Alpha 461d

Lantern Pharma presents positive LP-284 data in hematologic cancers at ASH 2021

Seeking Alpha 483d

Lantern Pharma announces $7M share repurchase authorization

Seeking Alpha 503d

Lantern Pharma EPS misses by $0.09

Seeking Alpha 504d

Lantern Pharma's AI platform gets better at enhancing precision medicine capabilities

PR Newswire 509d

Code Ocean Selected by Lantern Pharma to Power A.I. Focused Computational Research Environment for Oncology Drug Development

Benzinga 528d

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021

Benzinga 530d

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal

Benzinga 531d

The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout

Benzinga 537d

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug

RTTNews 567d

Lantern Pharma: FDA Grants Additional Orphan Drug Designation For LP-184 - Quick Facts

Benzinga 571d

54 Biggest Movers From Yesterday

Seeking Alpha 571d

YI, NRXP and LTRN among mid-day movers

Benzinga 577d

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data

RTTNews 577d

Lantern Pharma Reports Positive Data From Preclinical Study With LP-184 In Glioblastoma

PR Newswire 578d

Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration

PR Newswire 581d

Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer

RTTNews 586d

Lantern Pharma's LP-184 Gets Orphan Drug Designation In Treatment Of Pancreatic Cancer

PR Newswire 586d

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer

Seeking Alpha 586d

ANY, HOTH and ORPH among pre market gainers

PR Newswire 598d

Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights

RTTNews 601d

Lantern Pharma Reacquires Rights To Phase 2 Clinical Trial In Metastatic Prostate Cancer

PR Newswire 601d

Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S

Benzinga 603d

The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More

Benzinga 607d

62 Biggest Movers From Yesterday

Benzinga 608d

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street

PR Newswire 608d

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

Seeking Alpha 608d

CAH, SAV, HCA and EDU among pre-market gainers

Seeking Alpha 608d

Lantern Pharma rises on promising pre-clinical data for pancreatic cancer drug

Benzinga 724d

Highlights From Day 1 Of Benzinga's Biotech Small Cap Conference

Seeking Alpha 739d

Lantern Pharma EPS misses by $0.02